Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb December 11, 2023
Encouraging Initial Data from Randomized SELECT-AML-1 Ph 2 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine Announced December 11, 2023
Successful Completion of Safety Cohort and Positive DSMB Results from TCB008’s Trial in AML Patients Announced November 15, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
Ph 3 ENHANCE-2 study of magrolimab in patients with AML with TP53 mutations discontinued October 3, 2023
European Commission approved INAQOVI® (oral decitabine and cedazuridine) for 1L AML patients September 26, 2023
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML September 19, 2023
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML August 16, 2023
EMA Approves Clinical Trial Application (CTA) for AVC-201 for the Treatment of R/R AML and other CD123 Hematological Malignancies August 2, 2023
VANFLYTA First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML July 27, 2023
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, AML and MDS July 5, 2023
First Patient Dosed in Ph 2 IMpress Trial of Imetelstat in Patients with R/R AML or Higher Risk MDS June 21, 2023
